Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Obesity: early-phase trial registry
306 of 1,057 indexed Obesity trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3 of 28,963 conditions by registered trial count.
1,057 US clinical trials · 306 currently recruiting · #3 of 28,963 conditions by registered trial count
Obesity: 1,057 US clinical trials tracked, 306 recruiting.
Obesity is the subject of 1,057 registered US clinical trials on ClinicalTrials.gov, 306 of them currently open to new participants. 107 are in Phase 3-4 (later-stage) and 196 in Phase 1-2 (earlier-stage). The most active sponsor is Eli Lilly and Company, running 48 of these trials.
Open enrollment, early-phase tilt
Obesity has 1,057 registered US clinical trials, 306 of them open to new participants right now, about 29% of the total.
- 306
- recruiting participants now
- 29%
- of trials open to enrollment
- 107
- in Phase 3-4 (later-stage)
- 48
- top sponsor: Eli Lilly and Company
Corpus placement: #3 of 28,963 conditions by registered trial count on ClinicalTrials.gov-derived indexes. Registry reference only, not medical advice.
Key findings
What ClinicalTrials.gov does not surface for Obesity on its own pages , computed from the registry mirror as of 2026-07-11. Each line carries its own denominator so it can be quoted as it stands.
-
Obesity is recruiting below its size-band peers.
306 of 1,057 indexed trials (28.9%) are open to enrollment, against a 37.2% average across 135 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Obesity trials is spread across many organizations.
Eli Lilly and Company accounts for 48 of 1,057 trials (4.5%). 314 distinct sponsors appear on at least one study for this condition label.
-
Typical Obesity enrolment sits around 90 participants.
Median target enrolment is 90 among the 1,054 trials that report a genuine target (sentinel values excluded). 555 of those (52.7%) plan for fewer than 100 participants.
-
Obesity research is mostly interventional.
894 interventional and 163 observational studies make up this index (84.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
1,057 total, page 8 of 22
Reducing Weight and Elevated Stress Levels Using Educational and Behavioral Tools
H. Lee Moffitt Cancer Center and Research Institute
NCT04335799
Using Artificial Intelligence to Optimize Delivery of Weight Loss Treatment
Drexel University
NCT05231824
Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
Novo Nordisk A/S
NCT07220759
Teaching Kitchen Multisite Trial
Harvard School of Public Health (HSPH)
NCT05628649
Evaluation of the Safety and Efficacy of Revita® DMR on Body Weight Maintenance in Subjects With Obesity Who Have Achieved at Least 15% Weight Loss on Tirzepatide
Fractyl Health
NCT06484114
A Study of LY3537031 in Overweight, Obese, and Healthy Participants
Eli Lilly and Company
NCT06606106
Competency Based Approaches for Community Health 2
Vanderbilt University Medical Center
NCT04971044
A Research Study to See How Well Different Doses of CagriSema Help People With Excess Body Weight Lose Weight
Novo Nordisk A/S
NCT06388187
Trial to Optimize Just-in-Time Adaptive Intervention for Binge Eating & Weight-related Behaviors
Northwestern University
NCT06349460
Precision Nutrition and Metabolic Function
Washington University School of Medicine
NCT04131166
Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide
Novo Nordisk A/S
NCT07220642
EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway
Rhythm Pharmaceuticals
NCT05093634
A Study to Investigate Weight Management With LY3549492 Compared With Placebo in Adult Participants With Obesity or Overweight
Eli Lilly and Company
NCT06683508
A Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7204239 in Combination With Tirzepatide in Participants With Obesity or Overweight With At Least One Weight-related Comorbidity
Hoffmann-La Roche
NCT06965413
Success & Health Impacts For Transit Drivers During Onboarding
Oregon Health and Science University
NCT03730792
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Psoriatic Arthritis and Obesity or Overweight
Eli Lilly and Company
NCT06588296
Positive Airway Pressure, Sleep Apnea, and the Placenta (PAP-SAP)
The Miriam Hospital
NCT02412696
Ixekizumab Concomitantly Administered With Tirzepatide in Adults With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight
Eli Lilly and Company
NCT06588283
A Study to Evaluate the Efficacy and Safety of CX11 Tablets in Overweight/Obese Participants
Corxel Pharmaceuticals
NCT07011797
A Phase 2b Study to Evaluate the Efficacy and Safety of Once-Monthly MET097 in Adults With Obesity or Overweight
Metsera, a wholly owned subsidiary of Pfizer
NCT06973720
Long Term Outcomes of Bariatric Patients Treated With Surgery or Endoscopy
Johns Hopkins University
NCT03705416
A Study to Investigate Weight Management With Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Adults With Obesity or Overweight
Eli Lilly and Company
NCT06643728
Effects of Weight Loss Surgery on Bone Health in Adolescents
Massachusetts General Hospital
NCT02557438
Insulin Detemir in Obesity Management
Vanderbilt University
NCT01239550
Family Functioning in Obesity Treatment for Mexican Americans
Becky Marquez
NCT05120804
Engaging Men in Weight Loss With a Game-based mHealth and Neurotraining Program
Drexel University
NCT05408494
A Randomized Controlled Trial Comparing the Effectiveness of Different Treatment Options for Weight Management After Discontinuation of Semaglutide and Tirzepatide (GLP1 Transition Trial)
WW International
NCT06605703
A Phase 2b Study to Examine the Safety and Efficacy of Once-Weekly MET097 in Adults With Obesity or Overweight
Metsera, a wholly owned subsidiary of Pfizer
NCT06712836
Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)
Zealand Pharma
NCT06926842
Penn Medicine Food Market Study
University of Pennsylvania
NCT06283394
Neuroimaging Predictors of Bariatric Surgical Outcome
Hartford Hospital
NCT03582748
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
Novo Nordisk A/S
NCT05726227
A Study of Weekly Oral Ecnoglutide (VRB-101) in Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Verdiva Bio Dev Limited
NCT07281937
Miro-randomized Trial for Optimizing a JITAI to Reduce Dietary Lapses in Obesity Treatment
The Miriam Hospital
NCT04784585
The Dietary Guidelines 3 Diet Patterns Study (DG3D): Phase 2
University of South Carolina
NCT05254496
Efficacy Trial Healthy Dads, Healthy Kids for Hispanic Fathers and Children
Baylor College of Medicine
NCT05334420
Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health
Washington University School of Medicine
NCT02706262
Patients Navigators in Facilitating Weight Management in Obese Participants
M.D. Anderson Cancer Center
NCT03674229
Sequential or CombinaTion Anti-obesitY Medication With Muscle Preservation for Weight Loss and MaintEnance: A PragmAtic Randomized CoNtrolled Trial (STAY-LEAN Trial)
The Cleveland Clinic
NCT06854614
A Study of Tirzepatide (LY3298176) Once Weekly in Adolescent Participants Who Have Obesity or Overweight With Weight-Related Comorbidities
Eli Lilly and Company
NCT06075667
Effect of Metformin, a Drug Used to Treat Diabetes, vs Placebo
University of California, Los Angeles
NCT05949008
Feasibility and Acceptability of Incorporating Smartwatches Into an Exercise is Medicine Program in Older Individuals
Ohio State University
NCT06287255
Taldefgrobep Alfa in Adults With Overweight and Obesity
Biohaven Therapeutics
NCT07281495
BMI-based Vitamins in Obese Pregnant Women
Brigham and Women's Hospital
NCT02802566
Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
Washington University School of Medicine
NCT01104220
A Study of Tirzepatide (LY3298176) in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes
Eli Lilly and Company
NCT05536804
Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo
Skye Bioscience
NCT06577090
Preventing Diabetes in Latino Families
Arizona State University
NCT05228522
A Phase 2 Study Evaluating the Co-Administration of Bremelanotide With Tirzepatide for the Treatment of Obesity
Palatin Technologies
NCT06565611
Effects of Semaglutide in HIV-Associated Lipohypertrophy
Case Western Reserve University
NCT04019197
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 95 |
| Phase 2 | 101 |
| Phase 3 | 69 |
| Phase 4 | 38 |
Top Sponsors
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
What is open for Obesity right now
306 recruiting of 1,057 indexed (29% open).
Phase mix: 107 late (III/IV) vs 196 early (I/II) (early-phase heavy).
Top sponsor: Eli Lilly and Company (48 trials), 9 others listed. 50 shown below, recruiting first. #3 of 28,963 conditions by registered trial count.
How open-enrollment share is computed
Open share is recruiting_count divided by trial_count for this condition label in the public registry export. Status can change between pulls; treat the figure as a snapshot of research attention, not treatment availability.
Frequently Asked Questions
How many clinical trials are there for Obesity?
PlainTrial tracks 1,057 US clinical trials for Obesity, of which 306 are currently recruiting participants. Data sourced from ClinicalTrials.gov.
How do I find a recruiting trial for Obesity?
Use the trial list above filtered by "Recruiting" status, or visit our trial finder at /recruiting to search by condition and state. Always discuss trial participation with your healthcare provider before enrolling.
Is this data current?
Data is sourced from ClinicalTrials.gov and reflects our most recent data pull. Trial status may have changed since then. Always verify current information at ClinicalTrials.gov before making decisions about participation.
Related
Disclaimer: This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from ClinicalTrials.gov (National Library of Medicine). Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Source: ClinicalTrials.gov (NIH/NLM) ClinicalTrials.gov AACT registry · 2026 Trial counts and statuses sourced from ClinicalTrials.gov. Sponsor counts include both industry and federal/academic sponsors.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page aggregates every registered trial for this condition, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.